ArticleEndocrine, metabolic & immune disorders drug targets2026
Association of Glucose-Dependent Insulinotropic Polypeptide Receptor Polymorphisms rs3848460 and rs3895874 with the Risk of Gestational Diabetes Mellitus.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to examine the relationship between glucose-dependent insulinotropic polypeptide (GIP) polymorphisms rs3848460 and rs3895874 and the development of gestational diabetes mellitus (GDM) in Asian women. GIP, a hormone that stimulates insulin secretion and inhibits glucagon release, can be impacted by genetic variations, resulting in a reduced insulin response and elevated blood sugar levels that contribute to the development of GDM. To the best of our knowledge, only a limited number of studies have been conducted on the association between GIP gene polymorphisms and GDM.
methodsThe SNPscanTM genotyping assay was employed to genotype rs3848460 and rs3895874, with 502 control participants and 500 GDM patients selected for the study. ANOVA, T-test, chi-square test, logistic regression, and various other statistical tests were employed to investigate variations in genotypes and alleles and their associations with the risk of GDM.
resultsIn this study, significant differences were found in pre-BMI, age, systolic blood pressure, diastolic blood pressure, and parity between GDM and healthy subjects (P < 0.05). In the codominant model, GIP rs3848460 showed a significant association with an increased risk of GDM after adjusting (GG vs. AA: OR = 1.717; 95% CI: 1.070-2.754; P = 0.025. The recessive model GG vs. AG+AA suggests an elevated risk of GDM (adjusted OR of 1.635), with P =0.034. The GG genotype and G allele demonstrated a statistically significant increased risk with an adjusted OR of 1.760 (P =0.026) and an adjusted OR of 1.250 (P =0.029), respectively. The GG genotype and G allele were found to be associated with an increased risk of GDM in GIP rs3848460. Conversely, the risk of GDM was significantly lower in the dominant model (AA+GA vs. GG: OR = 0.605; 95% CI: 0.376-0.974; P = 0.039) for GIP rs3895874. The AA genotype and A allele were correlated with a decreased risk of GDM in GIP rs3895874 after adjustment with an OR of 0.803 (P =0.032).
conclusionGIP rs3848460 was found to be significantly associated with the risk of GDM. Conversely, the risk of GDM was significantly lower in rs3895874.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.